April 30 (Reuters) - CSL Ltd (CSL) :
- ARS PHARMACEUTICALS SUBMITS RESPONSE FOR NEFFY® (EPINEPHRINE NASAL SPRAY) MARKETING AUTHORIZATION APPLICATION TO EMA’S CHMP AND ENTERS LICENSE AGREEMENT WITH CSL SEQIRUS FOR COMMERCIALIZATION OF NEFFY IN AUSTRALIA AND NEW ZEALAND
- ARS PHARMACEUTICALS INC: CHMP OPINION ON NEFFY MARKETING AUTHORIZATION APPLICATION ANTICIPATED IN Q2 OF 2024
- Forums
- ASX - By Stock
- CSL
- News: CSL ARS Pharmaceuticals CHMP Opinion On Neffy Marketing Authorization Application Expected In...
News: CSL ARS Pharmaceuticals CHMP Opinion On Neffy Marketing Authorization Application Expected In...
Featured News
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$288.61 |
Change
1.590(0.55%) |
Mkt cap ! $139.7B |
Open | High | Low | Value | Volume |
$289.01 | $289.50 | $287.03 | $102.6M | 356.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2 | $288.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$288.79 | 200 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 137 | 303.090 |
6 | 371 | 303.040 |
1 | 5 | 300.000 |
1 | 1 | 297.250 |
1 | 40 | 294.420 |
Price($) | Vol. | No. |
---|---|---|
269.950 | 55 | 3 |
270.000 | 822 | 25 |
274.180 | 165 | 4 |
277.040 | 542 | 6 |
277.280 | 24 | 1 |
Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |